IASLC Staging Model for Mesothelioma Validated; Study Supports Continued Use of Model

IASLC Staging Model for Mesothelioma Validated; Study Supports Continued Use of Model

Press Release
Sep 11, 2023

­Media Contact: Chris Martin, MPH, IASLC Media Relations, 630.670.2745, cmartin@davidjamesgroup.com 

[Singapore, 10:05 a.m. SGT--September 12, 2023] — A model developed by the International Association for the Study of Lung Cancer in 2009 to help better stage mesothelioma cases performed well, according to an independent analysis presented today at The International Association for the Study of Lung Cancer (IASLC) 2023 Conference in Singapore 

Pleural mesothelioma is a rare but aggressive cancer primarily caused by asbestos exposure and presents complex challenges for effective staging and prognostication. The IASLC took a significant step in 2009 by establishing an international pleural mesothelioma database aimed at enhancing staging accuracy. Subsequently, in 2014, an analysis of data from 1995 to 2009 led to the identification of supplemental prognostic factors. The current study sought to validate and enhance these models using fresh clinical data.

The research, presented by Andrea Wolf, M.D., from The Icahn School of Medicine at Mount Sinai, in New York City, evaluated data from patients entered into the database between 2009 and 2019, constituting a validation cohort of 1,733 individuals. The study introduced additional variables for analysis, with model comparison based on Harrell’s C-index. Two distinct models were evaluated: one incorporating clinicopathological features and treatment (pathologic staging model), and the other encompassing parameters available at patient presentation (basic presentation model).

The training dataset, comprising 3,101 patients, revealed a significant optimal cut-point for mesothelin at 6.7 nmol/L using the running log-rank method. Univariate analysis highlighted anemia and elevated mesothelin levels as predictors of poorer survival. 

"Our study highlights the significant strides made in pleural mesothelioma staging. By refining and validating prognostic models, we are advancing our ability to tailor treatment strategies and improve patient outcomes,” said Dr. Wolf. “Continued efforts to gather and analyze data will improve prognostication and individualized patient care.”


About the IASLC:

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit http://www.iaslc.org for more information. 

About the WCLC:

The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2023.iaslc.org